Company Overview and News
Publishing two of the 8 new Week 2 breakout stocks that are available only to subscribers with better than 10% short-term upside potential. (245-6)
Getting adult patients to take part in a clinical trial is difficult. In the area of oncology, for example, only three to six percent of patients eligible for a study will take part in them, depending on whose numbers you believe. According to a study conducted by the Fred Hutchinson Cancer Research Center and the University of Washington, 20 percent of cancer trials will fail because of their inability to attract enough patients. (4-0)
I will establish the need for looking at biotech investing with a long-term outlook for achieving your goal. (57-2)
Welcome to the Caladrius Biosciences Third Quarter 2017 Business Update Conference Call. At this time, all participants are in a listen-only mode. Following managements prepared remarks; we will hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded today November 9, 2017. (19-0)
Timing consistent with plan to drive lead program TC-210 into the clinic in 2018 Team also strengthened with key hires in manufacturing and research (4-0)
Caladrius Biosciences, Inc. is a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. (19-0)
Welcome to the Caladrius Biosciences Second Quarter 2017 Results Conference Call. At this time, all participants are in a listen-only mode. Following managements prepared remarks we will hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded today August 10, 2017. (0-3)
Three separate developments have occurred this week surrounding type I diabetes, and the flurry of news deserves attention.
This report provides in-depth region wise and country wise analysis of the autologous cell therapy market. Stakeholders of this report include manufacturers of cell therapy products, raw material suppliers, cancer drug processing companies, and new players planning to enter the market.
WASHINGTON, DC--(Marketwired - Jul 19, 2017) - The Alliance for Regenerative Medicine (ARM) today announced the initial slate of companies selected to present at its upcoming Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017. (0-1)
Welcome to the Caladrius Biosciences 2017 First Quarter Corporate Results Conference Call. At this time, all participants are in a listen-only mode. Following managements prepared remarks we will hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded today May 18, 2017.
Global Regenerative Medicine Market Analysis & Forecast to 2021 report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials.
Research and Markets has announced the addition of the "Global Regenerative Medicine Market Analysis & Forecast to 2021 - Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries" report to their offering.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton